A 29-year-old male has been taking 1mg finasteride daily for 8 months and using 5% minoxidil with tretinoin but is experiencing increased hair shedding and higher DHT levels. He is concerned about the effectiveness of finasteride and has noticed low libido and occasional ED.
The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
A user with low ferritin and zinc levels is asking if others have seen hair improvement after taking iron supplements. They were prescribed minoxidil and finasteride by their doctor.
The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.
A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
Finasteride treatment is being considered, and it's advised to track DHT, testosterone, estradiol, and SHBG levels to monitor hormonal changes. These tests will help understand the treatment's impact.
A user discusses their experience with dissolving high concentrations of minoxidil in various ethanol/PG ratios and mentions difficulties with combining it with RU58841. They note that a 5% minoxidil solution remains stable, while higher concentrations tend to precipitate.
User reports 3-month progress using daily 1mg finasteride, 0.5ml minoxidil (2x daily), 0.5ml dutasteride, and derma rolling 0.5mm 1-2 times per week. They see increased density on crown and top of head, slight progress in corners and temples, and recently added cosmerna.
A 28-year-old man is considering whether to proceed with a hair transplant in February or continue using oral minoxidil, finasteride, and dermastamping, which have shown great progress in 3.5 months, to achieve desired results by his wedding in September 2026. Most responses suggest postponing the transplant to avoid potential "shock loss" and relying on the current treatment and hair fibers for the wedding.
A 30-year-old man has been treating his hair loss with 5% Minoxidil foam, a combination of 0.3% Finasteride and 6% Minoxidil at night, weekly dermastamping with 1.5 mm needles, and 1% ketoconazole shampoo 2-3 times a week for four months. He is asking for opinions on his hair regrowth and whether he can expect full recovery of his crown.
The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.
The conversation is about finding a legitimate online source for 17α-estradiol (Alfatradiol) powder to make a 0.1% solution for hair loss treatment. A user suggests Anagenica as a source.
A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
A 24-year-old male is experiencing hair loss due to low ferritin and vitamin D deficiency, and is using iron supplements, vitamin D3, finasteride, and ketoconazole shampoo for treatment. Users suggest increasing vitamin D and iron intake for better results and recommend consulting a professional for proper dosage.
User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
A user took 1.5 mg Finasteride and topical Minoxidil for 11 months, resulting in significant changes in blood values but no noticeable hair improvement. They experienced side effects like mood swings and increased visceral fat, leading them to stop Finasteride.
A user shared their 9-month post-hair transplant results with 4600 grafts, using only Nourkin hair vitamins, Vitamin D, and B12, and expressed satisfaction. The replies debated the necessity of medications like finasteride and minoxidil for maintaining hair health.
Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation discusses the potential for Verteporfin to reduce scarring, making hairline lowering surgeries more viable for men with mild hair loss. The user suggests that if scarring can be minimized, men might opt for hairline lowering instead of using grafts for other areas.
Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.